Collaborations & Alliances

Spark Therapeutics Earns $15M Pfizer Milestone

Advances Hemophilia B Gene therapy program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Spark Therapeutics has earned a $15 million milestone payment from Pfizer for achieving a pre-specified safety and efficacy profile in the ongoing hemophilia B Phase 1/2 trial of SPK-9001. SPK-9001 has received breakthrough therapy and orphan product designations from the U.S. FDA.   Spark Therapeutics received $20 million upfront under the agreement initiated in 2014, and a $15 million milestone in December 2015 for development progress. The company is eligible to receive as much as an additi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters